Published in Oncotarget on April 30, 2014
Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell (2014) 1.51
miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget (2016) 1.11
Regulation of Bim in Health and Disease. Oncotarget (2015) 0.95
ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res (2015) 0.94
Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta (2014) 0.93
Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis. Adv Exp Med Biol (2015) 0.92
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nat Cell Biol (2015) 0.81
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY) (2017) 0.79
Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. World J Gastroenterol (2016) 0.79
Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. Mol Cancer (2016) 0.79
Dependence of Human Colorectal Cells Lacking the FBW7 Tumor Suppressor on the Spindle Assembly Checkpoint. Genetics (2015) 0.77
Regulation of SOX10 stability via ubiquitination-mediated degradation by Fbxw7α modulates melanoma cell migration. Oncotarget (2015) 0.77
Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. Proc Natl Acad Sci U S A (2016) 0.76
The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function. EMBO J (2016) 0.75
TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Int J Gynecol Pathol (2016) 0.75
Role of E3 ubiquitin ligases in gastric cancer. World J Gastroenterol (2015) 0.75
The Janus face of p21. Mol Cell Oncol (2016) 0.75
Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3. Int J Mol Sci (2016) 0.75
miR‑223‑3p regulates cell growth and apoptosis via FBXW7 suggesting an oncogenic role in human testicular germ cell tumors. Int J Oncol (2016) 0.75
Poor prognosis in cholangiocarcinoma patients with low FBXW7 expression is improved by chemotherapy. Oncol Lett (2017) 0.75
The stability of Fbw7α in M-phase requires its phosphorylation by PKC. PLoS One (2017) 0.75
NF-κB p65 Overexpression Promotes Bladder Cancer Cell Migration via FBW7-Mediated Degradation of RhoGDIα Protein. Neoplasia (2017) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer (2008) 7.93
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science (2001) 6.29
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A (2004) 5.37
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer (2011) 5.12
Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature (2001) 5.07
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J (2004) 4.95
The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer (2003) 4.75
NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74
The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol (2007) 4.49
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol (2007) 4.35
Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 4.12
Mammalian Krüppel-like factors in health and diseases. Physiol Rev (2010) 4.09
MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer (2011) 3.91
Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem (2009) 3.89
Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell (2004) 3.85
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78
The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer (2012) 3.75
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell (2005) 3.47
Prolyl cis-trans isomerization as a molecular timer. Nat Chem Biol (2007) 3.45
Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog (2010) 3.44
Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab (2005) 3.43
The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res (2007) 3.40
MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov (2013) 3.33
The proteasome: a utility tool for transcription? Curr Opin Genet Dev (2006) 3.29
An ARC/Mediator subunit required for SREBP control of cholesterol and lipid homeostasis. Nature (2006) 3.23
Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem (2003) 2.94
NUMB controls p53 tumour suppressor activity. Nature (2008) 2.91
MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology (2008) 2.88
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer (2003) 2.88
Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol (2014) 2.87
The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science (2004) 2.83
MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer (2012) 2.78
Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci U S A (2004) 2.66
Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem (2003) 2.59
Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol (2008) 2.56
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer (2008) 2.53
Function and regulation of the Mediator complex. Curr Opin Genet Dev (2011) 2.51
MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett (2008) 2.48
A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol (2004) 2.45
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle (2011) 2.06
Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat Cell Biol (2005) 2.06
miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res (2011) 2.00
A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet (2011) 1.99
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function. Mol Cell (2011) 1.90
Numb regulates post-endocytic trafficking and degradation of Notch1. J Biol Chem (2009) 1.89
Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle (2005) 1.88
A component of the ARC/Mediator complex required for TGF beta/Nodal signalling. Nature (2002) 1.82
The multiple functions of Numb. Exp Cell Res (2009) 1.79
The SCF-Fbw7 ubiquitin ligase degrades MED13 and MED13L and regulates CDK8 module association with Mediator. Genes Dev (2013) 1.79
MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Mol Endocrinol (2005) 1.76
The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets (2010) 1.75
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res (2009) 1.70
Ubiquitin and proteasomes in transcription. Annu Rev Biochem (2012) 1.67
The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation. Cytokine (2011) 1.67
Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64
miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett (2010) 1.64
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta (2010) 1.59
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res (2008) 1.56
Notch inhibitors for cancer treatment. Pharmacol Ther (2013) 1.55
Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol Cell Biol (2010) 1.53
miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology (2011) 1.52
The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res (2010) 1.50
The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis (2013) 1.50
miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov (2012) 1.49
The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem (2010) 1.48
Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell (2012) 1.48
Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol (2012) 1.47
The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J (2010) 1.41
The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation. Oncogene (2010) 1.41
miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition. Cancer Genet (2011) 1.41
NUMB-ing down cancer by more than just a NOTCH. Biochim Biophys Acta (2010) 1.38
miR-223: infection, inflammation and cancer. J Intern Med (2013) 1.37
MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One (2012) 1.35
Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J Biol Chem (2006) 1.35
MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep (2011) 1.34
Siah-1 binds and regulates the function of Numb. Proc Natl Acad Sci U S A (2001) 1.33
Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res (2009) 1.32
Krüppel-like factors in cancer. Nat Rev Cancer (2013) 1.32
Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene (2011) 1.31
TRAP/SMCC/mediator-dependent transcriptional activation from DNA and chromatin templates by orphan nuclear receptor hepatocyte nuclear factor 4. Mol Cell Biol (2002) 1.31
Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci (2009) 1.30
Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med (2011) 1.28
miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma. J Biomed Sci (2011) 1.27
MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem (2010) 1.26
Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle (2007) 1.26
The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget (2011) 1.25
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res (2009) 4.24
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron (2004) 3.61
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell (2005) 3.51
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol (2009) 2.76
miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res (2010) 2.75
miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells (2009) 2.64
Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One (2010) 2.63
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol (2006) 2.60
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res (2010) 2.50
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol (2011) 2.31
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell (2012) 2.30
Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett (2011) 2.24
Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) (2011) 2.10
mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell (2011) 2.03
Multi-targeted therapy of cancer by genistein. Cancer Lett (2008) 2.02
Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell (2010) 1.95
Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem (2011) 1.94
Cdh1 regulates osteoblast function through an APC/C-independent modulation of Smurf1. Mol Cell (2011) 1.87
Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta (2002) 1.86
Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One (2011) 1.82
Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther (2005) 1.81
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells (2008) 1.78
Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol (2013) 1.73
2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl (2010) 1.66
Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64
Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat (2010) 1.61
Retracted Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J Cell Biochem (2009) 1.60
Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem (2007) 1.60
NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol (2008) 1.59
Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res (2008) 1.59
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res (2005) 1.57
Retracted FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat (2009) 1.57
CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res (2013) 1.48
Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell (2012) 1.48
Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem (2002) 1.45
Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res (2010) 1.40
Acetylation-dependent regulation of Skp2 function. Cell (2012) 1.40
Controlling the blood glucose of type 1 diabetes mice by co-culturing MIN-6 β cells on 3D scaffold. Pediatr Transplant (2015) 1.39
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood (2010) 1.38
Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med (2004) 1.37
Cellular signaling perturbation by natural products. Cell Signal (2009) 1.36
MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone (2013) 1.36
Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res (2009) 1.35
Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. Mol Cell (2010) 1.34
Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res (2011) 1.33
G protein-coupled receptor deorphanizations. Annu Rev Pharmacol Toxicol (2012) 1.33
Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-kappaB and Bcl-2. J Cell Biochem (2008) 1.32
Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs (2010) 1.32
Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther (2007) 1.30
The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta (2010) 1.29
Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell (2010) 1.29
Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res (2006) 1.28
Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PLoS One (2013) 1.27
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol (2010) 1.24
Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol (2013) 1.22
Retracted Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer (2006) 1.22
Skp2: a novel potential therapeutic target for prostate cancer. Biochim Biophys Acta (2011) 1.21
Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem Biophys Res Commun (2004) 1.21
Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J Biol Chem (2008) 1.20
HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood (2010) 1.20
Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol Cell Biol (2004) 1.19
Retracted In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer (2007) 1.19
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 1.18
Cdh1 regulates cell cycle through modulating the claspin/Chk1 and the Rb/E2F1 pathways. Mol Biol Cell (2009) 1.18
Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther (2010) 1.17
Mcl-1 ubiquitination and destruction. Oncotarget (2011) 1.17
Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod (2008) 1.17
A novel real-time PCR assay of microRNAs using S-Poly(T), a specific oligo(dT) reverse transcription primer with excellent sensitivity and specificity. PLoS One (2012) 1.16
Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol Cancer Ther (2006) 1.14
3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res (2009) 1.14
Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer (2013) 1.14
Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol (2009) 1.13
Stochastic variation in telomere shortening rate causes heterogeneity of human fibroblast replicative life span. J Biol Chem (2004) 1.13
Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic. Mutat Res (2011) 1.13
The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci (Landmark Ed) (2012) 1.12
Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant (2010) 1.11
MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer (2010) 1.11
Site-specific synthesis and properties of oligonucleotides containing C8-deoxyguanosine adducts of the dietary mutagen IQ. J Am Chem Soc (2004) 1.10
Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget (2013) 1.09
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res (2007) 1.08
Inhibition of cell growth and induction of apoptosis in non-small cell lung cancer cells by delta-tocotrienol is associated with notch-1 down-regulation. J Cell Biochem (2011) 1.08
The two faces of FBW7 in cancer drug resistance. Bioessays (2011) 1.08
Retracted Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways. Breast Cancer Res Treat (2010) 1.08
Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Cancer Lett (2013) 1.08
Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget (2011) 1.06
Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. Mol Cancer Res (2012) 1.05
Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Curr Drug Targets (2012) 1.05
MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell (2013) 1.05
SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. Cell Rep (2012) 1.03
3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res (2009) 1.03
Orphan GPCRs and their ligands. Pharmacol Ther (2005) 1.02
Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. Cancer Res (2006) 1.00
The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev (2010) 1.00
Emerging roles of the FBW7 tumour suppressor in stem cell differentiation. EMBO Rep (2011) 1.00